Clinical Trial Search

Primary: 50% Reduction in the Eczema Area and Severity Index Score (EASI-50) — 12; 9 Participants

Primary: SCORAD Change Score — 33.34 Change Score

Primary: Percent Change in the Number of Actinic Keratoses — -75 % change in number of actinic keratoses

Primary: Number of Participants With a Change in Clearance From Baseline — 1; 1; 9; 4 Participants

Primary: Proportion of SCORAD-50 Response at Week 16. — 5; 3 Participants

Primary: Change From Baseline in the m-EASI (Eczema Area Severity Index) Score. — 5.04; 4.77 units of a 0-12 scale — p=<0.05

Primary: Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points — 2 participants

Primary: Change in Treatment Symptoms — 3.9; 0.5; 0.37 score on a scale

Primary: Clinical PDT Response as Measured by Percent Change in AK Lesions From Baseline to 3 Months — 59.1; 72.5 Percent change of AK lesions

Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change

Primary: Mean Number of Facial Actinic Keratoses at Week 12 — 2.70 Lesions

Primary: Change in Lesion Counts in 25 cm2 Target Area Relative to Baseline. — -72; -37.5 lesions

Primary: Number of Pruritus Events in Last 30 Days — 7.4; 1.9 Events

Primary: Histological Lesion Clearance — 38.5; 69.2 percentage of complete histological clea

Primary: Mean Change From Baseline in Total Number of Treated Mild Lesions Per Side at Week 12 — 19.6; 20.0 number of lesions — p=0.8460

Primary: Number of Participants Who Experienced an Adverse Event — 472 participants

Primary: Percentage of Participants With Complete Response at Week 12 — 25.3; 23.0 percentage of participants

Primary: Complete Clearance Rate — 14; 7; 13; 8 participants — p=0.0041

Primary: Number of Participants Who Responded as Per Physician's Global Assessment (PGA) at Week 24 — 58; 14; 60; 30 Participants — p=<0.001

Primary: Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment — 0.53 proportion of participants

Primary: Ocular Symptoms and Signs Total Composite Score — 29.1; 4.7 units on a scale — p=0.002

Primary: Participant Complete Response Rate (CRR) — 68.4; 6.9 Percentage of participants

Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale

Primary: Percentage of Participants With Complete Response of Actinic Keratosis — 43; 32 percentage of participants

Primary: Change From Baseline in Eczema Area and Severity Index (EASI) Score at Day 43 — -2.64; -2.36 score on a scale — p=0.632

Primary: Percentage Change in SCORAD — -18.8; -11.7 percentage change

Primary: Percentage Change From Baseline in the Eczema Area and Severity Index (EASI) Score at Week 12. — -10.98; -25.99; -31.57 percent change — p=0.1308

Primary: Change From Baseline in Total Lesion Symptom Score (TLSS) — 6.3; 6.6; -1.9; -1.9 units on a scale — p=0.636

Primary: Number of Allergen-induced Eosinophils in the Skin — 11.95; 71.15 cells/mm2

Primary: Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis — -12.2; 9.3; -17.5 units on a scale — p=<0.05